Brandywine Global Investment Management LLC Buys 9,546 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Brandywine Global Investment Management LLC increased its stake in Jazz Pharmaceuticals by 2.5%, owning 391,276 shares valued at approximately $48.58 million.
• Jazz Pharmaceuticals reported a loss of ($8.25) earnings per share for the last quarter, missing analysts' estimates, despite achieving revenues of $1.05 billion.
• Institutional investors own 89.14% of Jazz Pharmaceuticals' stock, indicating strong institutional interest in the company.

Brandywine Global Investment Management LLC boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 2.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 391,276 shares of the specialty pharmaceutical company's stock after acquiring an additional 9,546 shares during the period. Brandywine Global Investment Management LLC owned 0.63% of Jazz Pharmaceuticals worth $48,577,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Nuveen LLC bought a new stake in Jazz Pharmaceuticals during the first quarter valued at approximately $62,362,000. Darwin Global Management Ltd. bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $59,668,000. Perpetual Ltd increased its holdings in shares of Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after buying an additional 357,784 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded up $1.53 during trading hours on Tuesday, hitting $119.20. The company's stock had a trading volume of 853,801 shares, compared to its average volume of 960,207. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The company's 50 day simple moving average is $111.94 and its two-hundred day simple moving average is $117.12. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company has a market cap of $7.23 billion, a P/E ratio of -17.71, a price-to-earnings-growth ratio of 7.42 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the company earned $5.30 earnings per share. Jazz Pharmaceuticals's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Robert W. Baird dropped their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Thirteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $181.43.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.